Objectives This study evaluates the overall survival (OS) and prognostic factors for neuroendocrine tumor (NET) patients treated with [177Lu]Lu-DOTATOC peptide receptor radionuclide therapy (PRRT). Core contributions include: Reporting a median OS o...
Markdown supported · ⌘↵ to post
No responses yet.